With refreshed brand eXoZymes sharpens pharmaceutical focus to drive platform leverage and long-term value creation
press releaseinvestor
With refreshed brand eXoZymes sharpens pharmaceutical focus to drive platform leverage and long-term value creationFebruary 10, 2026
Process Engineer (or Research Associate) - Fermentation & DSP
jobs
Process Engineer (or Research Associate) - Fermentation & DSPFebruary 6, 2026
Process Development Lead
jobs
Process Development LeadFebruary 6, 2026
Nasdaq's 'Amplify Spotlight'
heltzeninvestorpress clippingsvideo
Nasdaq: Michael B. Spector interviews CEO HeltzenFebruary 5, 2026
yahoo! finance
investorpress clippings
yahoo! finance: eXoZymes demonstrates end-to-end biomanufacturability of NCT, from reaction to high-purity isolated productJanuary 30, 2026
Pharma-grade NCT ready for partner testing
press releaseinvestornutraceuticalsscience
eXoZymes advancing commercial readiness with profound production metrics on initial NCT pilot runJanuary 29, 2026
Capital Markets Advisor, Sanjeev Srivastava, interviewed by Maxine Hoover
investorpress clippingsvideo
Beryl Elites: Interview with Capital Markets Advisor, Sanjeev SrivastavaJanuary 8, 2026
CEO Heltzen interviewed by Maxine Hoover at the Beryl Elites’ Investment Conference in New York City
heltzeninvestorpress clippingsvideo
Beryl Elites: What is Artificial Evolution - an interview with CEO HeltzenJanuary 7, 2026
IBT: AI meets enzymes
investornutraceuticalsmedicinepress clippings
International Business Times: AI meets enzymes - eXoZymes enables high-yield production of compounds previously impossible to makeDecember 17, 2025
CEO Michael Heltzen at the Beryl Elite's 'AI in Life Sciences' panel
heltzeninvestorpress clippings
Beryl Elites: AI's Billion-dollar Bet on Life Sciences - From Drug Discovery to Patient Impact (panel)December 15, 2025
Previous page
Page 1 of 11
Next page